Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open‐label, single‐arm, phase 3, and postmarketing clinical study

Masafumi Onodera, Toru Uchiyama, Tadashi Ariga, Masafumi Yamada, Takako Miyamura, Hironori Arizono, Tomohiro Morio

Open source

DOI
10.1002/iid3.917
Published
2023-07
Container
Immunity, Inflammation and Disease
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/iid3.917,
  title = {Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open‐label, single‐arm, phase 3, and postmarketing clinical study},
  author = {Masafumi Onodera and Toru Uchiyama and Tadashi Ariga and Masafumi Yamada and Takako Miyamura and Hironori Arizono and Tomohiro Morio},
  year = {2023},
  journal = {Immunity, Inflammation and Disease},
  doi = {10.1002/iid3.917},
  url = {https://doi.org/10.1002/iid3.917}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open‐label, single‐arm, phase 3, and postmarketing clinical study
AU  - Masafumi Onodera
AU  - Toru Uchiyama
AU  - Tadashi Ariga
AU  - Masafumi Yamada
AU  - Takako Miyamura
AU  - Hironori Arizono
AU  - Tomohiro Morio
PY  - 2023
JO  - Immunity, Inflammation and Disease
DO  - 10.1002/iid3.917
UR  - https://doi.org/10.1002/iid3.917
ER  - 

APA

Onodera, M., Uchiyama, T., Ariga, T., Yamada, M., Miyamura, T., Arizono, H., & Morio, T. (2023). Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open‐label, single‐arm, phase 3, and postmarketing clinical study. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.917

Source records